02162.HK
Keymed Biosciences Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 72.05
−1.23%Year over year
Reported trailing growth
- Revenue
- -5.7%
- EBITDA
- -67.4%
- EBIT
- -76.9%
- EPS
- +383.7%
- Free cash flow
- +35.3%
- Operating cash flow
- +39.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +91.1%
- EBITDA
- +14.8%
- EBIT
- +5.4%
- Net income
- +1.2%
- EPS
- +5.6%
- Free cash flow
- -4.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026